Irritable bowel syndrome

Internal Medicine Journal

Volumn 36, Issue 11, 2006, Pages 724-728

  Talley, N J ^a,b,c  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MAYO CLINIC   (United States)

Author keywords

Genetics; Infection; Inflammation; Irritable bowel syndrome; Therapy

Indexed keywords

ALOSETRON; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; DESIPRAMINE; IMIPRAMINE; LOPERAMIDE; MEBEVERINE; MELATONIN; PROBIOTIC AGENT; RIFAXIMIN; SEROTONIN; SEROTONIN 3 AGONIST; SEROTONIN 4 AGONIST; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; ANTICHOLINERGIC EFFECT; BACTERIAL OVERGROWTH; BLOATING; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIET THERAPY; DIETARY FIBER; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPNOSIS; IRRITABLE COLON; ISCHEMIC COLITIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT INDICATION;

HUMANS; IRRITABLE BOWEL SYNDROME;

EID: 33749847073     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2006.01217.x     Document Type: Review

References (31)

1. Drossman DA, Corrazziari E, Delvaux M, Spiller R, Talley NJ, Thompson WG et al. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates; 2006.
2. Drossman DA, Corrazziari E, Talley NJ, Thompson WG, Whitehead WE Rome II: The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology, and Treatment: A Multinational Consensus. McLean, VA: Degnon Associates; 2000.
3. Talley N, Spiller RC. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002; 360: 555-64.
4. Hammer J, Eslick G, Howell S, Altiparmak E, Talley NJ. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut 2004; 53: 666-72.
5. Guilera M, Balboa A, Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol 2005; 100: 1174-84.
6. Boyce PM, Talley NJ, Burke C, Koloski NA. Epidemiology of the functional gastrointestinal disorders diagnosed according to Rome II criteria: an Australian population-based study. Intern Med J 2006; 36: 28-36.
7. Locke GR 3rd, Zinsmeister AR, Fett SL, Melton LJ 3rd, Talley NJ. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil 2005; 17: 29-34.
8. Gwee KA. Irritable bowel syndrome in developing countries - a disorder of civilization or colonization? Neurogastroenterol Motil 2005; 17: 317-24.
9. Mearin F, Perez-Oliveras M, Perello A, Vinyet J, Ibanez A, Coderch J et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005; 129: 98-104.
10. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003; 98: 1578-83.
11. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-51.
12. Talley NJ. Serotoninergic neuroenteric modulators. Lancet 2001; 358: 2061-8.
13. Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 349-57.
14. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 1657-64.
15. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292: 852-8.
16. Koloski NA, Talley NJ, Boyce PM. A history of abuse in community subjects with irritable bowel syndrome and functional dyspepsia: the role of other psychosocial variables. Digestion 2005; 72: 86-96.
17. Mayer EA, Berman S, Suyenobu B, Labus J, Mandelkern MA, Naliboff BD et al. Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain 2005; 115: 398-409.
18. Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005; 54: 601-7.
19. Saito YA, Petersen GM, Locke GRI, Talley NJ. The genetics of irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 1057-65.
20. Cash BD, Chey WD. Irritable bowel syndrome - an evidence-based approach to diagnosis. Aliment Pharmacol Ther 2004; 19: 1235-45.
21. Spiegel BM, Gralnek IM, Bolus R, Chang L, Dulai GS, Naliboff B et al. Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome? Gastrointest Endosc 2005; 62: 892-9.
22. Spiegel BM, DeRosa VP, Gralnek IM, Wang V, Dulai GS. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004; 126: 1721-32.
23. Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005; 17: 332-40.
24. Robinson A, Lee V, Kennedy A, Middleton L, Rogers A, Thompson DG et al. A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome. Gut 2006; 55: 643-8.
25. Talley NJ. Conquering Irritable Bowel Syndrome. Hamilton, Ontario, Canada: BC Decker; 2005.
26. Quartero A, Meineche-Schmidt V, Muris JW, Rubin G, de Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005; (2): CD 003460.
27. Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum AL. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20: 1253-69.
28. Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005; 100: 115-23.
29. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101: 326-33.
30. Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 2005; 54: 1402-7.
31. Whitehead WE. Hypnosis for irritable bowel syndrome: the empirical evidence of therapeutic effects. Int J Clin Exp Hypn 2006; 54: 7-20.